Navigation Links
Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
Date:11/14/2013

PRINCETON, N.J., Nov. 14, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") announced today that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.  

Utilizing the funding provided with the earlier Phase I grant, Dermalogix established a novel screening paradigm to effectively identify potent therapeutic compounds from its isoprenylcysteine (IPC) technology platform. These screening efforts resulted in the identification of several IPC compounds possessing anti-inflammatory and anti-microbial activity. This Phase II funding will be used to select a lead drug candidate and commence IND-enabling safety/toxicology studies.

"This award is further validation of the potential for IPC compounds in dermatology. We are pleased to be awarded this grant by the NIH and our objective continues to be the development of our technology with the goal of delivering therapeutic agents to treat skin disease," stated Maxwell Stock, President & CEO.

Dermalogix has a successful track record in receiving and executing on NIH funding. Recently, with National Institute of Allergy and Infectious Diseases (NIAID) SBIR funding, Dermalogix announced that an Investigational New Drug (IND) Application to evaluate IPC compound SIG990 in rosacea has been cleared by the FDA. Dr. Eduardo Perez, VP of R&D and Business Development stated, "Building on the experience and momentum provided by SIG990, we believe successful development of our novel class of topical IPC compounds will provide an important additional, and potentially better, therapeutic option for people suffering atopic dermatitis."  

About Signum Dermalogix
Signum Dermalogix is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit: www.signumdermalogix.com


'/>"/>
SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
2. IntelligentMDx Receives FDA Clearance for IMDx C. difficile for Abbott m2000 Assay, Completes Move of Corporate Headquarters to Waltham
3. Numotion Receives 2013 MDA Company of the Year Award
4. EndoShape Receives 510(k) Clearance for Polymer Embolization Device
5. Actinobac Biomed Founder Receives Two Awards For Promising New Drug
6. ARMGO Pharma Receives Research Grant Award from Kennedys Disease Association to Support Advancement of Rycal Compounds
7. Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
8. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
9. ARRAYit Corporation Receives Purchase Order from ChemBio
10. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
11. Par Pharmaceuticals Karen OConnor Receives 2013 Cardinal Health Supply Chain Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the ... be in the beginning stages of an IPO. ... medications with the average cost of a prescription epilepsy drug being $450.00-$1200.00 ... AXIUM PHARMACEUTICALS, ... Another staggering figure is the fact that Americans ...
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... ... made the 2017 Inc. 5000 with a three-year sales growth of 49 ... private companies and comprises the most comprehensive look at America’s independent entrepreneurs. This ...
(Date:8/23/2017)... Arizona (PRWEB) , ... August 23, 2017 , ... ... in the top 20% of hospitals nationally that earned the designation of High ... list. An overall rating of high performing indicates a hospital was significantly better than ...
(Date:8/23/2017)... ... 23, 2017 , ... MobilityWorks ®, the nation's largest ... 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka ... marking the twelfth year that the company has been included on the list. ...
(Date:8/23/2017)... ... 2017 , ... Virsys12, a Salesforce Gold Consulting Partner, continues ... of Kevin Keelan as a Senior Account Executive, based in the Denver, Colorado ... working with Virsys12 senior leadership to extend and develop the firm’s client portfolio ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... of the American Academy of Orthopaedic Surgeons , points out that therapeutic ... suffering from pain or injury. According to the report, a wider scope of ...
Breaking Medicine News(10 mins):